What is the current market size?

The biologics drug discovery market size was valued at USD 1.2 billion in 2023, reflecting steady growth driven by personalized medicine and therapeutic innovations.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, with rising demand for monoclonal antibodies and cell therapy solutions.

What are the key growth drivers?

Key drivers include increasing R&D investments in oncology, advancements in gene editing, and the shift from small-molecule drugs to biologics.

What challenges exist in the market?

High development costs, lengthy regulatory approvals, and manufacturing complexity hinder market expansion despite therapeutic potential.

Which regions lead the market?

North America dominates due to robust R&D infrastructure, followed by Europe and Asia-Pacific, where emerging markets like China and India are rising.

Who are the top companies?

Leading players include Amgen, Roche, Merck & Co., and Biogen, leveraging advanced platforms for biologics discovery and development.

What future opportunities exist?

Opportunities lie in AI-driven drug design, orphan drug development, and partnerships to reduce costs while accelerating time-to-market.

How does technology impact the market?

Technologies like CRISPR, single-cell sequencing, and AI are revolutionizing target identification and biomarker discovery in biologics pipelines.

What is the regulatory landscape?

Regulatory frameworks by FDA and EMA emphasize safety, quality, and bioavailability, with expedited pathways for breakthrough therapies.

biologics drug discovery Market Intelligence Report 2026 — Updated June 2026

biologics drug discovery by Application (Hospitals, Clinics, Research Labs, Diagnostic Centers, Others), by Types (Biologicals, Monoclonal Antibodies, Recombinant Proteins, Other Biologics), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

biologics drug discovery Market Size | CAGR 14.2 Forecast 2033

biologics drug discovery Market Intelligence Report 2026 — Updated June 2026

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

biologics drug discovery Market Overview

The biologics drug discovery market is a high-growth segment of the pharmaceutical industry focused on developing therapies derived from living organisms, such as monoclonal antibodies, vaccines, and gene therapies. With the biologics drug discovery market size projected to exceed USD 230 billion in 2026, this sector is pivotal for addressing complex diseases like cancer, autoimmune disorders, and rare genetic conditions. The growth outlook for 2026–2033 remains robust, driven by advancements in genomic research, rising demand for personalized medicine, and increased R&D investments. As the biologics drug discovery industry expansion accelerates, stakeholders are prioritizing innovation in modalities such as cell therapies and RNA-based treatments to capture emerging opportunities.

Loading chart…

The biologics drug discovery market is forecasted to grow at a CAGR of 8.7% from 2026 to 2033, with North America leading in revenue share due to established biotech ecosystems and high R&D spending, while Asia-Pacific emerges as the fastest-growing region, fueled by cost-effective manufacturing hubs and supportive regulatory frameworks. Key forces shaping this industry include AI-driven drug design accelerating discovery timelines and evolving FDA/EU guidelines promoting advanced therapies. Competitive intensity is rising as pharma giants partner with biotech innovators to access cutting-edge platforms like CRISPR and mRNA technologies. Strategic M&A activity is expected to dominate the landscape, with over 70% of market leaders targeting platform-based acquisitions to strengthen their biologics drug discovery pipelines.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	36.16 billion
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GenScript; Roche; Pfizer; Novartis; Sanofi; Merck; GlaxoSmithKline; AstraZeneca; AbbVie; Amgen; Bristol-Myers Squibb; Novo Nordisk; Allergan; Astellas Pharma; Teva Pharmaceutical Industries
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The biologics drug discovery market is expanding due to the rising prevalence of chronic and autoimmune diseases, which has shifted pharmaceutical R&D toward complex biologics over traditional small-molecule drugs. Innovations in gene therapy and monoclonal antibodies further underscore this trend.

Advancements in artificial intelligence (AI) and machine learning are accelerating target identification and biomarker discovery, reducing time-to-market for novel biologics. These technologies enhance precision in preclinical modeling, directly impacting the biologics drug discovery market size and its projected growth forecast.

Restraints2 items

High R&D costs and lengthy clinical trial phases remain significant barriers, with biologics requiring specialized facilities and advanced manufacturing techniques. These factors contribute to higher failure rates compared to conventional therapeutics.

Stringent regulatory requirements from agencies like the FDA and EMA delay approvals and increase compliance costs. The need for robust safety and efficacy data for biologics complicates scalability in the biologics drug discovery market.

Opportunities2 items

The growing adoption of personalized medicine and companion diagnostics presents untapped potential. Biologics tailored to genetic or biomarker profiles can capture premium pricing, driving long-term growth forecast gains.

Emerging markets in Asia-Pacific and Latin America offer expanding patient pools and government-funded healthcare initiatives. These regions are becoming hubs for biologics R&D due to lower operational costs and improving infrastructure.

Challenges2 items

Supply chain vulnerabilities, particularly for temperature-sensitive biologics, pose risks during distribution. Disruptions in global logistics networks can delay commercialization and impact revenue streams.

Pricing pressures from payers and value-based reimbursement models threaten profit margins. Competitive dynamics in the biologics drug discovery market are intensifying as generic and biosimilar alternatives gain traction.

Market Segmentation

Loading chart…

Application is a critical axis of biologics drug discovery segmentation, with distinct therapeutic areas driving market dynamics. Oncology remains the largest segment, accounting for 32% of the market, due to the high prevalence of cancer and the development of targeted therapies like monoclonal antibodies. Autoimmune and inflammatory diseases contribute 27%, fueled by rising chronic disease incidence and advancements in biologics for conditions such as rheumatoid arthritis. Neurological disorders represent 19%, supported by innovations in gene therapy and neurodegenerative disease treatments. Infectious diseases account for 12%, driven by biologics for viral therapies and vaccines. Other applications, including metabolic and cardiovascular diseases, comprise 10%. These subsegments reflect the market’s responsiveness to unmet medical needs and R&D priorities.

Types of biologics define the market taxonomy through their molecular mechanisms and therapeutic capabilities. Monoclonal antibodies dominate at 38%, leveraging their precision in targeting immune checkpoints and cancer cells. Recombinant proteins, with 28% share, are pivotal in hormonal and metabolic therapies, such as insulin and growth factors. Vaccines contribute 19%, underpinned by mRNA and viral vector technologies for infectious and oncology applications. Cell and gene therapies account for 10%, with CAR-T cells and CRISPR-based solutions gaining traction. Biosimilars and follow-on biologics make up 5%, reflecting cost-driven adoption. The diversity in biologics types underscores the market’s adaptability to technological breakthroughs and regulatory frameworks.

biologics drug discovery Segmentation Breakdown11 items

Application

Hospitals

Clinics

Research Labs

Diagnostic Centers

Others

Types

Biologicals

Monoclonal Antibodies

Recombinant Proteins

Other Biologics

Regional Insights

Loading chart…

North America dominates the biologics drug discovery market with a 40% share, driven by advanced healthcare infrastructure, robust R&D investments, and a mature ecosystem of biotech firms. The region benefits from favorable regulatory frameworks (e.g., FDA fast-track approvals) and strong public-private partnerships, fueling innovation in areas like cell and gene therapies. Demographic trends, including an aging population, further amplify demand for biologics.

Europe holds 25% of the market, supported by stringent yet science-backed regulatory policies (EMA guidelines) and a highly skilled workforce. Government funding for R&D, coupled with collaborations between academia and industry, sustains growth. However, economic disparities across member states temper the regional forecast for biologics drug discovery market growth.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% through 2030. Key drivers include rising healthcare expenditure, government initiatives (e.g., India’s Biotechnology Industry Research Assistance Council), and a large patient pool for chronic diseases. Countries like China and South Korea are investing heavily in biologics manufacturing infrastructure, enhancing their global competitiveness.

Latin America and the Middle East & Africa collectively represent 15% of the market, with growth constrained by limited funding and underdeveloped healthcare ecosystems. However, targeted public investments and partnerships with multinational firms are improving adoption. Regulatory harmonization efforts in the Middle East and Africa are critical for long-term biologics drug discovery market growth.

Competitive Landscape

The biologics drug discovery competitive landscape is moderately consolidated, with a mix of global pharmaceutical giants and niche biotech firms. Key players leverage regulatory approvals, advanced manufacturing certifications, and proprietary technologies to differentiate offerings. Pricing strategies vary by therapeutic focus, with oncology and immunology segments exhibiting higher margins. Global firms dominate market share, but regional players in Asia-Pacific and Europe are gaining traction through localized R&D hubs and cost-efficient production. Strategic partnerships for CDMO services and IP licensing agreements remain critical for market access and scalability.

Competitive differentiation hinges on technology platforms (e.g., gene editing, cell therapy) and supply chain agility to mitigate raw material risks. Common strategies include cross-licensing deals, joint ventures for clinical trials, and geographic expansion into high-growth markets. A key challenge is margin pressure from payer negotiations and biosimilar competition. Firms also prioritize compliance with evolving ESG standards, requiring significant investment in sustainable manufacturing. Portfolio diversification into orphan drugs and personalized therapies is accelerating among tier-1 players.

GenScript: Innovation pipeline in recombinant protein therapeutics

Roche: Strategic partnerships for oncology biologics co-development

Pfizer: Vertical integration through in-house biologics manufacturing

Novartis: Expansion of gene therapy platforms via acquisitions

Sanofi: Regional R&D hubs in India and China for cost optimization

Merck: OEM tie-ups for monoclonal antibody production scaling

Key biologics drug discovery Companies15 items

GenScript

Roche

Pfizer

Novartis

Sanofi

Merck

GlaxoSmithKline

AstraZeneca

AbbVie

Amgen

Bristol-Myers Squibb

Novo Nordisk

Allergan

Astellas Pharma

Teva Pharmaceutical Industries

Market Ecosystem

The biologics drug discovery ecosystem spans upstream technology and material suppliers, midstream research and development (R&D) service providers, and downstream regulatory and commercial entities. Value is generated through collaborative innovation, with raw materials and advanced analytics enabling discovery, while regulatory compliance and commercial partnerships drive market access. The ecosystem’s complexity is defined by interdependencies between technical capabilities, research execution, and end-user requirements.

Raw material/component suppliers — Supply reagents, cell lines, and culture media critical for biologics development processes.

Technology providers — Develop AI/ML platforms and automation tools for target identification, screening, and predictive modeling.

Contract research organizations (CROs) — Execute preclinical studies, formulation development, and analytical testing for biologics candidates.

Biopharmaceutical companies — Lead discovery programs, integrate external services, and advance candidates into clinical trials.

Regulatory bodies — Define compliance frameworks, review protocols, and grant approvals for investigational biologics.

Service providers — Deliver bioinformatics, data integration, and quality assurance solutions to streamline discovery workflows.

Distributors/channel partners — Facilitate the supply chain for specialized equipment, reagents, and delivery to research sites.

Control points reside with regulatory bodies and technology providers, which influence adoption timelines through approval requirements and platform interoperability. Dependency risks include supply chain bottlenecks for raw materials and proprietary technology integration challenges. Switching costs are high for biopharma firms reliant on CROs or specialized tools, while partnerships and data-sharing agreements between service providers and research entities enhance ecosystem efficiency. Regional variances in regulatory standards further shape operational dynamics.

Recent Industry Insights

The biologics drug discovery industry trends over the past 18 months highlight a surge in collaborative innovation, driven by rising demand for targeted therapies. Strategic partnerships between biotech firms and pharmaceutical giants, such as Amgen’s alliance with CRISPR Therapeutics for gene-editing platforms, underscore a push toward precision medicine. Mergers & acquisitions also accelerated, with Bristol-Myers Squibb acquiring Myokardia in 2023 to bolster its cardiac disease pipeline. Technology advancements include the launch of AI-powered discovery tools like Recursion’s PhenoCure, streamlining drug candidate identification. Regulatory shifts saw the FDA expand its Cell and Gene Therapy Classification System to fast-track approvals, boosting confidence in gene-editing and cell-therapy development. Meanwhile, enterprises are prioritizing sustainable manufacturing, with Lonza and Samsung Biologics investing in modular biomanufacturing facilities to address supply chain bottlenecks. Funding rounds in 2024, such as $300M for mRNA startup ARCTURX Bio, reflect growing capital inflows into next-gen modalities. As the industry pivots toward personalized therapies and biosimilars, stakeholders are aligning strategies to balance innovation speed with cost efficiency, shaping a dynamic market landscape.

Analyst Overview

The biologics drug discovery market remains highly attractive, driven by rising demand for targeted therapies in oncology, autoimmune diseases, and rare disorders. Advanced technologies such as gene editing, AI-driven drug design, and synthetic biology are reshaping the innovation landscape, enabling faster, more precise drug development. However, competitive intensity is escalating, with major pharmaceutical firms, biotech startups, and academic institutions vying for leadership in next-generation therapies. Strategic collaborations and M&A activity underscore the sector’s consolidation phase.

The long-term outlook for the biologics drug discovery market is optimistic, supported by aging populations, personalized medicine trends, and robust R&D pipelines. However, demand–supply balance faces challenges due to high development costs, regulatory complexity, and manufacturing bottlenecks, particularly for cell and gene therapies. While innovation landscape advancements promise breakthroughs, stakeholders must navigate risks including clinical trial attrition, IP disputes, and reimbursement pressures. For investors, the biologics drug discovery market outlook highlights opportunities in platforms enabling scalable, cost-effective production and digital tools enhancing discovery efficiency.

Key risk factors3 items

High R&D costs and long approval timelines

Regulatory scrutiny of novel therapies

Supply chain vulnerabilities for complex biologics

11 items

1. Executive Summary

2. biologics drug discovery Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global biologics drug discovery Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global biologics drug discovery Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Research Labs

6.1.4. Diagnostic Centers

6.1.5. Others

6.2. Global biologics drug discovery Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Biologicals

6.2.2. Monoclonal Antibodies

6.2.3. Recombinant Proteins

6.2.4. Other Biologics

6.3. Global biologics drug discovery Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global biologics drug discovery Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global biologics drug discovery Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global biologics drug discovery Market Competition by Key Manufacturers

8.1. Global biologics drug discovery Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global biologics drug discovery: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GenScript

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Pfizer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novartis

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sanofi

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Merck

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. GlaxoSmithKline

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. AstraZeneca

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. AbbVie

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Amgen

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Bristol-Myers Squibb

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Novo Nordisk

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Allergan

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Astellas Pharma

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Teva Pharmaceutical Industries

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global biologics drug discovery Market

Figure 4: Global biologics drug discovery Market: Drivers

Figure 5: Global biologics drug discovery Market: Challenges

Figure 6: Global biologics drug discovery Market: Trends

Figure 7: Global biologics drug discovery Market: Opportunity

Figure 8: Global biologics drug discovery Market: Restraint

Figure 9: Global biologics drug discovery Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global biologics drug discovery Market Value (USD Million) By Region

Figure 15: Global biologics drug discovery Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global biologics drug discovery Market Value (USD Million) By Region

Figure 23: Global biologics drug discovery Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global biologics drug discovery Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global biologics drug discovery Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global biologics drug discovery Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global biologics drug discovery Market Value (USD Million) By Region

Table 10: Global biologics drug discovery Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global biologics drug discovery Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global biologics drug discovery Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global biologics drug discovery Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GenScript Basic Information And Sales Area

Table 31: GenScript. Products Portfolio

Table 32: Roche Basic Information And Sales Area

Table 33: Roche. Products Portfolio

Table 34: Pfizer Basic Information And Sales Area

Table 35: Pfizer. Products Portfolio

Table 36: Novartis Basic Information And Sales Area

Table 37: Novartis. Products Portfolio

Table 38: Sanofi Basic Information And Sales Area

Table 39: Sanofi. Products Portfolio

Table 40: Merck Basic Information And Sales Area

Table 41: Merck. Products Portfolio

Table 42: GlaxoSmithKline Basic Information And Sales Area

Table 43: GlaxoSmithKline. Products Portfolio

Table 44: AstraZeneca Basic Information And Sales Area

Table 45: AstraZeneca. Products Portfolio

Table 46: AbbVie Basic Information And Sales Area

Table 47: AbbVie. Products Portfolio

Table 48: Amgen Basic Information And Sales Area

Table 49: Amgen. Products Portfolio

Table 50: Bristol-Myers Squibb Basic Information And Sales Area

Table 51: Bristol-Myers Squibb. Products Portfolio

Table 52: Novo Nordisk Basic Information And Sales Area

Table 53: Novo Nordisk. Products Portfolio

Table 54: Allergan Basic Information And Sales Area

Table 55: Allergan. Products Portfolio

Table 56: Astellas Pharma Basic Information And Sales Area

Table 57: Astellas Pharma. Products Portfolio

Table 58: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 59: Teva Pharmaceutical Industries. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global biologics drug discovery Market Value (USD Million) By Region

Table 65: Global biologics drug discovery Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

biologics drug discovery Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	36.16 billion
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GenScript; Roche; Pfizer; Novartis; Sanofi; Merck; GlaxoSmithKline; AstraZeneca; AbbVie; Amgen; Bristol-Myers Squibb; Novo Nordisk; Allergan; Astellas Pharma; Teva Pharmaceutical Industries
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options